A New Pragmatic Design for Dose Escalation in Phase 1 Clinical Trials Using an Adaptive Continual Reassessment Method

BMC Cancer - United Kingdom
doi 10.1186/s12885-019-5801-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Continual Reassessment Method for Dose Escalation Clinical Trials in Oncology: A Comparison of Prior Skeleton Approaches Using AZD3514 Data

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Robust EM Continual Reassessment Method in Oncology Dose Finding

Journal of the American Statistical Association
UncertaintyStatisticsProbability
2011English

A Trivariate Continual Reassessment Method for Phase I/Ii Trials of Toxicity, Efficacy, and Surrogate Efficacy

Statistics in Medicine
EpidemiologyStatisticsProbability
2012English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Miscellanea. A Stopping Rule for the Continual Reassessment Method

Biometrika
StatisticsProbabilityUncertaintyApplied MathematicsBiological SciencesAgriculturalMathematics
1998English

Continual Reassessment and Related Designs in Dose-Finding Studies

Statistics in Medicine
EpidemiologyStatisticsProbability
2011English

Escalation With Overdose Control Using Time to Toxicity for Cancer Phase I Clinical Trials

PLoS ONE
Multidisciplinary
2014English

The Role of Age on Dose-Limiting Toxicities (DLTs) in Phase I Dose-Escalation Trials.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Practical Modifications to the Time-To-Event Continual Reassessment Method for Phase I Cancer Trials With Fast Patient Accrual and Late-Onset Toxicities

Statistics in Medicine
EpidemiologyStatisticsProbability
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy